1. Home
  2. NOV vs COGT Comparison

NOV vs COGT Comparison

Compare NOV & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOV Inc.

NOV

NOV Inc.

HOLD

Current Price

$17.28

Market Cap

5.7B

Sector

Industrials

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$34.79

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOV
COGT
Founded
1862
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
6.5B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
NOV
COGT
Price
$17.28
$34.79
Analyst Decision
Hold
Buy
Analyst Count
14
13
Target Price
$16.71
$30.17
AVG Volume (30 Days)
3.8M
2.5M
Earning Date
02-04-2026
02-24-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$8,775,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.84
$3.72
52 Week High
$17.84
$43.73

Technical Indicators

Market Signals
Indicator
NOV
COGT
Relative Strength Index (RSI) 62.07 43.79
Support Level $16.67 $32.93
Resistance Level $17.84 $36.88
Average True Range (ATR) 0.53 1.62
MACD 0.14 -0.72
Stochastic Oscillator 77.03 24.28

Price Performance

Historical Comparison
NOV
COGT

About NOV NOV Inc.

NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: